Study Drug LOXO-101 Shows Tumor Regression in Varied Cancers
University of Texas MD Anderson Cancer CenterA phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.